Are you over 21 years old?
This website requires you to be 21 years or older to enter our website and see the content.
Your access is restricted because of your age.
$242.00
TB10mg+BPC10mg+GHK50mg
70mg*10vials
If you are searching for GLOW peptide blend for sale (TB-500 10mg + BPC-157 10mg + GHK-Cu 50mg), sourcing from a verified manufacturer is essential to ensure purity, consistency, and reliable research outcomes. Prime Solution Peptides is a licensed peptide manufacturer supplying high–quality research compounds for regenerative studies, tissue repair research, and cellular signaling pathway analysis.
We operate under controlled laboratory standards.
We verify purity through analytical testing.
We provide full documentation for every production batch.
The GLOW blend is a multi-peptide formulation combining TB-500 (Thymosin Beta-4 fragment), BPC–157, and GHK-Cu. This advanced combination is designed for research involving tissue regeneration, cellular repair mechanisms, angiogenesis, and extracellular matrix remodeling. Each peptide contributes to complementary pathways, making this blend valuable for integrated regenerative and biological response studies.
Direct manufacturer sourcing ensures maximum product integrity, traceability, and consistent long-term supply.
We support:
Is the GLOW blend available in bulk quantities?
Yes. We offer scalable manufacturing with volume-based pricing.
Do you provide Certificates of Analysis?
Yes. Each batch includes verifiable COA documentation.
Do you ship within the USA?
Yes. Orders are fulfilled through our U.S. distribution network.
What purity level is provided?
≥98% purity verified via HPLC (custom specifications available upon request).
We combine advanced peptide synthesis technology with strict quality control systems to deliver dependable research-grade compounds at scale.
$29.00 – $55.00Price range: $29.00 through $55.00
$88.00
This website uses cookies to improve your experience.
By using this website you agree to our Privacy Policy.
Reviews
There are no reviews yet.